Skip Navigation


JAC Advance Access originally published online on June 13, 2008
Journal of Antimicrobial Chemotherapy 2008 62(3):464-468; doi:10.1093/jac/dkn228
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
62/3/464    most recent
dkn228v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Payne, B. A. I.
Right arrow Articles by Chadwick, D. R.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Payne, B. A. I.
Right arrow Articles by Chadwick, D. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Low prevalence of transmitted antiretroviral drug resistance in a large UK HIV-1 cohort

Brendan A. I. Payne1, Emmanuel F. Nsutebu2, Ewan R. Hunter3, Olufunso Olarinde4, Paul Collini5, James A. T. Dunbar6, Medhat S. T. Basta7, James W. T. Elston8, Matthias L. Schmid3, Hiten Thaker8 and David R. Chadwick1,*

1 Department of Infection and Travel Medicine, James Cook University Hospital, Middlesbrough, UK 2 Department of Infectious Diseases and Sexual Health, Bradford Teaching Hospitals Foundation Trust, Bradford, UK 3 Department of Infection and Tropical Medicine, Newcastle General Hospital, Newcastle-upon-Tyne, UK 4 Department of Genitourinary Medicine, Royal Hallamshire Hospital, Sheffield, UK 5 South Yorkshire Regional Department of Infection and Tropical Medicine, Royal Hallamshire Hospital, Sheffield, UK 6 Department of Infection and Travel Medicine, St James’ Hospital, Leeds, UK 7 Department of Genitourinary Medicine, Newcastle General Hospital, Newcastle-upon-Tyne, UK 8 Department of Infection and Tropical Medicine, Castle Hill Hospital, Cottingham, East Yorkshire, UK

Received 30 December 2007; returned 27 March 2008; revised 8 May 2008; accepted 19 May 2008

* Corresponding author: Tel: +44-1642-850850; Fax: +44-1642-854017; E-mail: davidr.chadwick{at}stees.nhs.uk

Objectives: To describe current practice in testing for transmitted antiretroviral drug resistance (TDR) and the prevalence of TDR in a large UK HIV-1 cohort.

Methods: The study includes a retrospective analysis of newly diagnosed HIV-1-infected patients presenting to eight HIV clinics in the north of England between March 2005 and March 2007. Resistance mutations were defined by IAS-USA. Predicted phenotypes were calculated by the Stanford University database.

Results: Five hundred and fifty-eight patients were studied, of whom 394 (70.6%) had heterosexually acquired HIV and 377 (67.6%) were infected outside the UK. TDR testing was performed in 406 patients (72.8%). Thirteen of 392 viral resistance profiles (3.3%) showed genotypic TDR. There was no significant association between TDR and any demographic or risk factor or baseline CD4 count. In particular, rates of TDR were similar in white British (6/147, 4.1%) and black African (7/224, 3.1%) patients. The numbers of patients with TDR to individual drug classes were: nucleoside reverse transcriptase inhibitors, 2 (0.5%); non-nucleoside reverse transcriptase inhibitors, 7 (1.8%); and protease inhibitors, 4 (1.0%). No patients had multi-class resistance detected. Eleven patients (2.8%) were predicted to have significant phenotypic resistance to at least one drug.

Conclusions: In a large unselected UK cohort, with high coverage of TDR testing, the prevalence of TDR was low and is in accordance with recent data, showing a decrease in the prevalence of TDR in the UK. Differences in population mix did not appear to explain this low rate.

Keywords: HIV drug resistance/resistance mutations , antiretroviral therapy , knowledge/attitude/practice studies


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.